Batch release is the documented quality decision about one lot of a product. A set of passing test results supports that decision but is not the same thing, and a released lot has not been shown to help any patient.
In the US, drug production and control records are reviewed and approved by the quality control unit before a batch is released or distributed, and any unexplained discrepancy or failure of a batch to meet a specification must be thoroughly investigated whether or not the batch has been distributed (21 CFR 211.192). The decision therefore draws on test results with their methods and acceptance criteria, manufacturing and deviation records, and the identity of the lot and product version; a certificate of analysis can summarise results but does not replace that review. FDA's 2022 guidance on out-of-specification results says the practice of repeating a test until a passing result is obtained and then disregarding the failing results without scientific justification is 'testing into compliance', which it calls unscientific and objectionable under CGMP. That guidance covers chemistry-based laboratory testing; it says it is not intended to address biological assays, so a copied retest procedure cannot be assumed to fit a cell or potency assay. A lot can be released, held pending review or rejected; a result that has not arrived is neither a pass nor a failure. Release of a lot is a quality decision, separate from regulatory authorisation of the product, from a patient's eligibility, and from evidence of clinical benefit.
Shares CDMO (contract development and manufacturing organisation), mRNA and lipid nanoparticle manufacturing, Autologous CAR-T manufacturing, batch by batch.
Shares Good manufacturing practice (GMP), Cell-therapy release and potency testing, Radiopharmaceutical GMP and releasing a drug that decays.
Shares Cell-therapy release and potency testing, mRNA and lipid nanoparticle manufacturing.
Shares Cell-therapy release and potency testing, Autologous CAR-T manufacturing, batch by batch.
Shares CDMO (contract development and manufacturing organisation), mRNA and lipid nanoparticle manufacturing.
Shares mRNA and lipid nanoparticle manufacturing, Autologous CAR-T manufacturing, batch by batch.
Shares Cell-therapy release and potency testing, Autologous CAR-T manufacturing, batch by batch.
Shares Cell-therapy release and potency testing, Autologous CAR-T manufacturing, batch by batch.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/